Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.49 |
| ▸ | CTSD | P07339 | 7/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517610 | 0.90 | BACE1 (0.64) | BACE1BACE2CTSD | |
| SCHEMBL4530756 | 0.89 | BACE1 (0.57) | BACE1BACE2CTSDREN | |
| SCHEMBL4920367 | 0.87 | BACE1 (0.61) | BACE1BACE2CTSDREN | |
| SCHEMBL4923210 | 0.87 | BACE1 (0.61) | BACE1BACE2CTSDREN | |
| SCHEMBL4924947 | 0.83 | BACE1 (0.58) | BACE1BACE2CTSDREN | |
| SCHEMBL4516420 | 0.82 | BACE1 (0.67) | BACE1BACE2CTSDREN | |
| SCHEMBL4920280 | 0.82 | BACE1 (0.56) | BACE1BACE2CTSD | |
| SCHEMBL4532979 | 0.82 | BACE1 (0.55) | BACE1BACE2CTSD | |
| SCHEMBL5067242 | 0.81 | BACE1 (0.49) | BACE1BACE2CTSD | |
| SCHEMBL4512566 | 0.80 | BACE1 (0.62) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | BACE1 14/4885BACE2 30/4885CTSD 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.